PARP1 and posterior cortical atrophy: Moreover, since PARP1 inhibitors olaparip and niraparib are effective in PCa treatment particularly in patients that have homologous recombination repair alterations, [49,50] we tested whether FAM111A depletion altered the efficacy of the PARP1 inhibitors.